Penetration of topotecan into cerebrospinal fluid after intravenous injection

Onkologie

Volumn 21, Issue SUPPL. 4, 1998, Pages 22-24

  Stewart, C F ^a,b   Gajjar, A J ^a   Heideman, R L ^a   Houghton, P J ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Hycamtin; Penetration into cerebrospinal fluid; Topoisomerase I inhibitor; Topotecan

Indexed keywords

DNA TOPOISOMERASE; HYDROXYACID; LACTONE DERIVATIVE; TOPOTECAN;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; CENTRAL NERVOUS SYSTEM METASTASIS; CENTRAL NERVOUS SYSTEM TUMOR; CEREBROSPINAL FLUID; CHILDHOOD CANCER; CLINICAL TRIAL; CONFERENCE PAPER; DRUG CEREBROSPINAL FLUID LEVEL; DRUG PENETRATION; EPENDYMOMA; GLIOMA; HUMAN; MEDULLOBLASTOMA; TUMOR GROWTH;

EID: 0032445752     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000054980     Document Type: Conference Paper

References (13)

1. Stewart CF, Zamboni WC, Crom WR, Gajjar AJ, Heideman RL, Furman WL, Meyer WH, Houghton PJ, Pratt CB: Topoisomerase I interactive drugs in children with cancer. Invest New Drugs 1996;14: 37-47.
2. Houghton PJ, Cheshire PJ, Hallman JD, Lutz L, Friedman HS, Danks MK, Houghton JA: Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995;36: 393-403.
3. Friedman HS, Houghton PJ, Schold SC, Keir S, Bigner DD: Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 1994;34:171-174.
4. Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, Giaccone G, Schaefer B, Wanders J, Verweij J: Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease. J Clin Oncol 1997;15:2090-2096.
5. Blaney SM, Cole DE, Balis FM, Godwin K, Poplack DG: Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. Cancer Res 1993;53:725-727.
6. Grochow LB, Rowinsky EK, Johnson R, Ludeman S, Kaufmann SH, McCabe FL, Hurowitz L, DeLisa A, Donehower RC: Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab Dispos 1992;20:706-713.
7. Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Raphael B, Vinci RZ: Phase I trial of low-dose continuous topotecan infusion in patients with cancer: An active and well-tolerated regimen. J Clin Oncol 1994;12:553-559.
8. O'Dwyer PJ, LaCreta FP, Haas NB, Halbherr T, Frucht H, Goosenberg E, Yao KS: Clinical, pharmacokinetic and biological studies of topotecan. Cancer Chemother Pharmacol 1994;34(suppl):S46-52.
9. Stewart CF, Baker SD, Heideman RL, Jones D, Crom WR, Pratt CB: Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. J Clin Oncol 1994; 12:1946-1954.
10. Tubergen DG, Stewart CF, Pratt CB, Zamboni WC, Winick N, Santana VM, Dryer ZA, Kurtzberg J, Bell B, Grier H, Vietti TJ: Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: A Pediatric Oncology Group Study. J Pediatr Hematol Oncol 1996;18: 352-361.
11. Pratt CB, Stewart C, Santana, VM, Bowman L, Furman W, Ochs J, Marina N, Kuttesch JF, Heideman R, Sandlund JT: Phase I study of topotecan for pediatric patients with malignant solid tumors. J Clin Oncol 1994;12:539-543.
12. Zamboni WC, Stewart CF, Thompson J, Santana VM, Cheshire PJ, Richmond LB, Xiaolong Luo, Poquette C, Houghton JA, Houghton PJ: Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J Natl Cancer Inst 1998;90:505-511.
13. D'Argenio DZ, Schumitzky A: ADAPT II User's Guide. USC, Los Angeles: Biomedical Simulations Resource, 1990.